Article Text

Download PDFPDF

Correspondence response
Allopurinol dose relative to renal function and risk of hypersensitivity reactions
  1. Richard Day1,2,
  2. Shuen-Iu Hung3,
  3. Wen-Hung Chung4
  1. 1Department of Clinical Pharmacology & Toxicology, St Vincent's Hospital Sydney Ltd, Darlinghurst, New South Wales, Australia
  2. 2Faculty Of Medicine, St Vincent's Clinical School, University of New South Wales, Darlinghurst, New South Wales, Australia
  3. 3Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan
  4. 4Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan
  1. Correspondence to Professor Richard Osborne Day, Department of Clinical Pharmacology & Toxicology, St Vincent's Hospital Sydney Ltd, Darlinghurst, NSW 2010, Australia;{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We thank Dr Corrado Campochiaro for the comments1 on our paper examining the risks for severe cutaneous adverse reactions (SCAR) to allopurinol.2 Dr Campochiaro notes that the ratio of baseline dose of allopurinol to glomerular filtration rate was not different to controls without allopurinol-SCAR in our patients with renal impairment (estimated glomerular filtration rate (eGFR) <30 mL/min) compared with Stamp et al,3 who found a higher ratio in their patients with SCAR. First, Dr Campochiaro asks if any of our subjects were being dialysed as this reduces plasma oxypurinol concentrations. They were not. There is a difference in the two studies, however, that might explain this apparent contrast, apart from the additional point made by Dr Campochiaro that our patients had worse renal function than the patients in the Stamp et al study. In our study, the ratio of dose to eGFR is that on presentation with SCAR. We do not have data on starting doses for our patients or controls. This contrasts with Stamp et al who have starting doses as well as doses at the time of SCAR. Larger prospective controlled studies examining the hypothesis of Stamp et al that lower commencing doses in relation to eGFR might reduce the risk of allopurinol-SCAR are needed.


View Abstract


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles